There have recently been several advancements in the world of biomaterial design and tissue validation thanks to the BIODESIGN consortium. Currently, a partnership of 19 research and clinical teams from academic centres, small biotech and large pharmaceutical companies is designing and developing state-of-the-art therapeutic approaches, with the aim to help treat traumatic damage and degenerative diseases in humans and alleviate patient suffering.
Tricking algae's biological clock to remain in its daytime setting can dramatically boost the amount of valuable compounds that these simple marine plants can produce when they are grown in constant light.
Designing new drugs based on the body's own molecules will be the focus of a new Center for Biopharmaceuticals that was launched at the Faculty of Health and Medical Sciences on 1 November. The Center will help solve the pharmaceutical challenges of the future in the field of biological drugs.
Entrepreneurial scientists in the synthetic biology space can benefit from a new GBP 10M investment fund that opens for business today. The new fund will help companies in the early stages of their journey towards sustainability, through investment, strategic support and leveraging private capital.
Riboswitches are RNA segments that switch genes on and off, either during DNA transcription or during protein translation, but little is known about the precise workings of this process. A study at SISSA uncovers some of the basic steps in this complex mechanism and paves the way for future research.
Scientists looking to create a potent blend of enzymes to transform materials like corn stalks and wood chips into fuels have developed a test that should turbocharge their efforts. The work revolves around the fungus Trichoderma reesei, which introduced itself to US troops during World War II by chewing through their tents in the Pacific theater. Now the fungus is a star in the world of biofuels.